PARP inhibitors, use early in the first-line maintenance therapy setting but with caution

Affiliations

• ¹ Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
• ² Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy.
• ³ Department of Obstetrics and Gynecology, Gynecologic Cancer Center, Asan Cancer Institute, Asan Medical Center, University of Ulsan, Seoul, South Korea.